Redeye initiates coverage of Faron Pharmaceuticals, a Finnish biotech company focused on developing next-generation immunotherapy, its three promising pipeline projects provides multiple inflection points ahead. We argue that lead candidate Bexmarilimab offers first-in-class blockbuster potential in difficult-to-treat cancers. Further positive clinical data from ongoing trials can position it as a prime acquisition target for Big Pharma.